EUVIMEDEUVIMED entdecken
Crossref

Thymoquinone and its derivatives against breast cancer with HER2 positive: in silico studies of ADMET, docking and QSPR

Adinda Adelia Wulandari, Achmad Aziz Choiri, Fitria, Tri Widiandani iD

Journal of Basic and Clinical Physiology and Pharmacology · 25.06.2021 · 32 (4) · 393-401

DOI: 10.1515/jbcpp-2020-0431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology, online erschienen am 25.06.2021. Verfasst von Adinda Adelia Wulandari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy Universitas Airlangga, Surabaya, Indonesia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Benzoquinones, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Ministry of Education and Culture Republic Indonesia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The high prevalence of HER2-positive breast cancer has become a significant concern in the health sector. The problem is more complex with the side effects of breast cancer drugs currently used. Thymoquinone (TQ), the main bioactive compound in Nigella sativa , has been shown to have anticancer activity. However, it is necessary to modify the structure of the thymoquinone derivatives to improve drug bioavailability. This study uses an in silico approach to predict pharmacokinetic profile, docking, quantitative structure–properties relationship (QSPR) of new thymoquinone-derived compounds as candidates cytotoxic agent for breast cancer with HER-2 positive.

Methods

The prediction of ADMET was using pkCSM online. Molecular docking was used to determine thymoquinone derivatives activity using Molegro Virtual Docker version 5.5 by docking the thymoquinone derivatives to the HER2 receptor targets, PDB ID 3PP0 and QSPR analysis using the IBM SPSS 21 version.

Results

The 35 thymoquinone derivatives showed good physicochemical and absorption properties and not hepatotoxic, so they are suitable for oral drugs. The molecular docking of 35 thymoquinone derivatives against 3PP0 proteins showed better activity than thymoquinone. One of the thymoquinone derivatives, TQ 15, showed the largest negative RS value, meaning that is predicted to have the highest anticancer activity. Based on the QSPR analysis, the essential parameter in determining 35 thymoquinone derivatives activity was the lipophilic and steric parameter.

Conclusions

Based on in silico test, thymoquinone derivative, TQ 15, had the potential to be further developed as a HER2-positive breast cancer drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBenzoquinonesNeoplasmsComputer SimulationMolecular Docking SimulationPharmaceutical Preparations

Stichwörter der Autor:innen

Molegro Virtual DockerQSPRbreast cancer; HER2pkCSMthymoquinone

Substanzen

Antineoplastic AgentsBenzoquinonesPharmaceutical Preparationsthymoquinone

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy Universitas Airlangga, Surabaya, Indonesia.

ORCID-Profile: Tri Widiandani

Förderung

  • Ministry of Education and Culture Republic Indonesia

Zitieren

APA

Wulandari, A. A., Choiri, A. A., Fitria, & Widiandani, T. (2021). Thymoquinone and its derivatives against breast cancer with HER2 positive: in silico studies of ADMET, docking and QSPR. Journal of Basic and Clinical Physiology and Pharmacology, 32(4), 393-401. https://doi.org/10.1515/jbcpp-2020-0431

Vancouver

Wulandari AA, Choiri AA, Fitria, Widiandani T. Thymoquinone and its derivatives against breast cancer with HER2 positive: in silico studies of ADMET, docking and QSPR. Journal of Basic and Clinical Physiology and Pharmacology. 2021;32(4):393-401. doi:10.1515/jbcpp-2020-0431

BibTeX
@article{Wulandari2021,
  author = {Wulandari, Adinda Adelia and Choiri, Achmad Aziz and Fitria and Widiandani, Tri},
  title = {Thymoquinone and its derivatives against breast cancer with HER2 positive: in silico studies of ADMET, docking and QSPR},
  journal = {Journal of Basic and Clinical Physiology and Pharmacology},
  year = {2021},
  volume = {32},
  number = {4},
  pages = {393--401},
  doi = {10.1515/jbcpp-2020-0431}
}
Kostenlos starten →